{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:51:31Z","timestamp":1788306691268,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,7,29]],"date-time":"2023-07-29T00:00:00Z","timestamp":1690588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,29]],"date-time":"2023-07-29T00:00:00Z","timestamp":1690588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Alexion Pharma GK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s12185-023-03630-x","type":"journal-article","created":{"date-parts":[[2023,7,29]],"date-time":"2023-07-29T12:01:20Z","timestamp":1690632080000},"page":"419-431","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Real-world safety profile of eculizumab in patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, or generalized myasthenia gravis: an integrated analysis of post-marketing surveillance in Japan"],"prefix":"10.1007","volume":"118","author":[{"given":"Jun-ichi","family":"Nishimura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Murai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Shimono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahisa","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Fukamizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirozumi","family":"Akiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichi","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,29]]},"reference":[{"issue":"18","key":"3630_CR1","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1182\/blood-2014-02-522128","volume":"124","author":"RA Brodsky","year":"2014","unstructured":"Brodsky RA. Paroxysmal nocturnal hemoglobinuria. Blood. 2014;124(18):2804\u201311. https:\/\/doi.org\/10.1182\/blood-2014-02-522128.","journal-title":"Blood"},{"issue":"11","key":"3630_CR2","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/nbt1344","volume":"25","author":"RP Rother","year":"2007","unstructured":"Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol. 2007;25(11):1256\u201364. https:\/\/doi.org\/10.1038\/nbt1344.","journal-title":"Nat Biotechnol"},{"issue":"17\u201318","key":"3630_CR3","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/s0161-5890(96)00078-8","volume":"33","author":"TC Thomas","year":"1996","unstructured":"Thomas TC, Rollins SA, Rother RP, Giannoni MA, Hartman SL, Elliott EA, et al. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol. 1996;33(17\u201318):1389\u2013401. https:\/\/doi.org\/10.1016\/s0161-5890(96)00078-8.","journal-title":"Mol Immunol"},{"key":"3630_CR4","unstructured":"SOLIRIS\u00ae (eculizumab) 300 mg for intravenous infusion. Interview Form, revised December 2020 (16th edition). Available from https:\/\/soliris.jp\/-\/media\/soliris_jp\/document-slide\/interview_form.pdf. Accessed 19 July 2023. [In Japanese]."},{"issue":"3","key":"3630_CR5","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1053\/j.seminhematol.2018.04.009","volume":"55","author":"F Fakhouri","year":"2018","unstructured":"Fakhouri F, Loirat C. Anticomplement treatment in atypical and typical hemolytic uremic syndrome. Semin Hematol. 2018;55(3):150\u20138. https:\/\/doi.org\/10.1053\/j.seminhematol.2018.04.009.","journal-title":"Semin Hematol"},{"issue":"7","key":"3630_CR6","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/ped.13044","volume":"58","author":"H Kato","year":"2016","unstructured":"Kato H, Nangaku M, Hataya H, Sawai T, Ashida A, Fujimaru R, et al. Clinical guides for atypical hemolytic uremic syndrome in Japan. Pediatr Int. 2016;58(7):549\u201355. https:\/\/doi.org\/10.1111\/ped.13044.","journal-title":"Pediatr Int"},{"issue":"17","key":"3630_CR7","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/NEJMra0902814","volume":"361","author":"M Noris","year":"2009","unstructured":"Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361(17):1676\u201387. https:\/\/doi.org\/10.1056\/NEJMra0902814.","journal-title":"N Engl J Med"},{"issue":"1","key":"3630_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/cen3.12180","volume":"6","author":"H Murai","year":"2015","unstructured":"Murai H. Japanese clinical guidelines for myasthenia gravis: Putting into practice. Clin Exp Neuroimmunol. 2015;6(1):21\u201331. https:\/\/doi.org\/10.1111\/cen3.12180.","journal-title":"Clin Exp Neuroimmunol."},{"issue":"3","key":"3630_CR9","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s40265-018-0875-9","volume":"78","author":"S Dhillon","year":"2018","unstructured":"Dhillon S. Eculizumab: A review in generalized myasthenia gravis. Drugs. 2018;78(3):367\u201376. https:\/\/doi.org\/10.1007\/s40265-018-0875-9.","journal-title":"Drugs"},{"issue":"12","key":"3630_CR10","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/s1474-4422(17)30369-1","volume":"16","author":"JF Howard Jr","year":"2017","unstructured":"Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): A phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017;16(12):976\u201386. https:\/\/doi.org\/10.1016\/s1474-4422(17)30369-1.","journal-title":"Lancet Neurol"},{"issue":"1","key":"3630_CR11","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s12185-010-0748-9","volume":"93","author":"Y Kanakura","year":"2011","unstructured":"Kanakura Y, Ohyashiki K, Shichishima T, Okamoto S, Ando K, Ninomiya H, et al. Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: The AEGIS clinical trial. Int J Hematol. 2011;93(1):36\u201346. https:\/\/doi.org\/10.1007\/s12185-010-0748-9.","journal-title":"Int J Hematol"},{"issue":"23","key":"3630_CR12","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","volume":"368","author":"CM Legendre","year":"2013","unstructured":"Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368(23):2169\u201381. https:\/\/doi.org\/10.1056\/NEJMoa1208981.","journal-title":"N Engl J Med"},{"key":"3630_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-022-03287-y","author":"T Ikezoe","year":"2022","unstructured":"Ikezoe T, Noji H, Ueda Y, Kanda Y, Okamoto S, Usuki K, et al. Long-term follow-up of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: post-marketing surveillance in Japan. Int J Hematol. 2022. https:\/\/doi.org\/10.1007\/s12185-022-03287-y.","journal-title":"Int J Hematol"},{"key":"3630_CR14","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfac150","author":"S Ito","year":"2022","unstructured":"Ito S, Hataya H, Ashida A, Hamada R, Ishikawa T, Ishikawa Y, et al. Eculizumab for paediatric patients with atypical haemolytic-uremic syndrome: full dataset analysis of post-marketing surveillance in Japan. Nephrol Dial Transplant. 2022. https:\/\/doi.org\/10.1093\/ndt\/gfac150.","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"3630_CR15","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/s10157-018-1610-2","volume":"23","author":"S Ito","year":"2019","unstructured":"Ito S, Hidaka Y, Inoue N, Kaname S, Kato H, Matsumoto M, et al. Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: Interim analysis of post-marketing surveillance. Clin Exp Nephrol. 2019;23(1):112\u201321. https:\/\/doi.org\/10.1007\/s10157-018-1610-2.","journal-title":"Clin Exp Nephrol"},{"issue":"1","key":"3630_CR16","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10157-018-1609-8","volume":"23","author":"H Kato","year":"2019","unstructured":"Kato H, Miyakawa Y, Hidaka Y, Inoue N, Ito S, Kagami S, et al. Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: Interim analysis of post-marketing surveillance. Clin Exp Nephrol. 2019;23(1):65\u201375. https:\/\/doi.org\/10.1007\/s10157-018-1609-8.","journal-title":"Clin Exp Nephrol"},{"key":"3630_CR17","doi-asserted-by":"publisher","first-page":"175628642110019","DOI":"10.1177\/17562864211001995","volume":"14","author":"H Murai","year":"2021","unstructured":"Murai H, Suzuki S, Hasebe M, Fukamizu Y, Rodrigues E, Utsugisawa K. Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: Interim analysis of post-marketing surveillance. Ther Adv Neurol Disord. 2021;14:17562864211001996. https:\/\/doi.org\/10.1177\/17562864211001995.","journal-title":"Ther Adv Neurol Disord"},{"issue":"5","key":"3630_CR18","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1007\/s12185-016-2065-4","volume":"104","author":"H Ninomiya","year":"2016","unstructured":"Ninomiya H, Obara N, Chiba S, Usuki K, Nishiwaki K, Matsumura I, et al. Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan. Int J Hematol. 2016;104(5):548\u201358. https:\/\/doi.org\/10.1007\/s12185-016-2065-4.","journal-title":"Int J Hematol"},{"issue":"2","key":"3630_CR19","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/bjh.15790","volume":"185","author":"G Soci\u00e9","year":"2019","unstructured":"Soci\u00e9 G, Caby-Tosi MP, Marantz JL, Cole A, Bedrosian CL, Gasteyger C, et al. Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis. Br J Haematol. 2019;185(2):297\u2013310. https:\/\/doi.org\/10.1111\/bjh.15790.","journal-title":"Br J Haematol"},{"issue":"4","key":"3630_CR20","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1007\/s12185-020-02934-6","volume":"112","author":"K Ishiyama","year":"2020","unstructured":"Ishiyama K, Nakao S, Usuki K, Yonemura Y, Ikezoe T, Uchiyama M, et al. Results from multinational phase 3 studies of ravulizumab (ALXN1210) versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria: Subgroup analysis of Japanese patients. Int J Hematol. 2020;112(4):466\u201376. https:\/\/doi.org\/10.1007\/s12185-020-02934-6.","journal-title":"Int J Hematol"},{"issue":"6","key":"3630_CR21","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1182\/blood-2018-09-876805","volume":"133","author":"AG Kulasekararaj","year":"2019","unstructured":"Kulasekararaj AG, Hill A, Rottinghaus ST, Langemeijer S, Wells R, Gonzalez-Fernandez FA, et al. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: The 302 study. Blood. 2019;133(6):540\u20139. https:\/\/doi.org\/10.1182\/blood-2018-09-876805.","journal-title":"Blood"},{"key":"3630_CR22","doi-asserted-by":"publisher","unstructured":"Lee JW, Sicre de Fontbrune F, Wong Lee Lee L, Pessoa V, Gualandro S, F\u00fcreder W, et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: The 301 study. Blood. 2019; 133(6):530\u20139. https:\/\/doi.org\/10.1182\/blood-2018-09-876136.","DOI":"10.1182\/blood-2018-09-876136"},{"issue":"6","key":"3630_CR23","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.kint.2020.01.035","volume":"97","author":"E Rondeau","year":"2020","unstructured":"Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, et al. The long-acting C5 inhibitor, ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome na\u00efve to complement inhibitor treatment. Kidney Int. 2020;97(6):1287\u201396. https:\/\/doi.org\/10.1016\/j.kint.2020.01.035.","journal-title":"Kidney Int"},{"issue":"13","key":"3630_CR24","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1001\/jama.293.13.1653","volume":"293","author":"RP Rother","year":"2005","unstructured":"Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA. 2005;293(13):1653\u201362. https:\/\/doi.org\/10.1001\/jama.293.13.1653.","journal-title":"JAMA"},{"issue":"5","key":"3630_CR25","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1080\/10245330701562634","volume":"12","author":"WJ Savage","year":"2007","unstructured":"Savage WJ, Brodsky RA. New insights into paroxysmal nocturnal hemoglobinuria. Hematology. 2007;12(5):371\u20136. https:\/\/doi.org\/10.1080\/10245330701562634.","journal-title":"Hematology"},{"issue":"1","key":"3630_CR26","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/j.1476-5381.2010.00643.x","volume":"160","author":"G Bagdy","year":"2010","unstructured":"Bagdy G, Riba P, Kecskem\u00e9ti V, Chase D, Juh\u00e1sz G. Headache-type adverse effects of NO donors: vasodilation and beyond. Br J Pharmacol. 2010;160(1):20\u201335. https:\/\/doi.org\/10.1111\/j.1476-5381.2010.00643.x.","journal-title":"Br J Pharmacol"},{"issue":"2","key":"3630_CR27","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.nurt.2010.03.006","volume":"7","author":"J Olesen","year":"2010","unstructured":"Olesen J. Nitric oxide-related drug targets in headache. Neurotherapeutics. 2010;7(2):183\u201390. https:\/\/doi.org\/10.1016\/j.nurt.2010.03.006.","journal-title":"Neurotherapeutics"},{"issue":"5\u20136","key":"3630_CR28","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1159\/000491439","volume":"10","author":"DAC Heesterbeek","year":"2018","unstructured":"Heesterbeek DAC, Angelier ML, Harrison RA, Rooijakkers SHM. Complement and bacterial infections: from molecular mechanisms to therapeutic applications. J Innate Immun. 2018;10(5\u20136):455\u201364. https:\/\/doi.org\/10.1159\/000491439.","journal-title":"J Innate Immun"},{"key":"3630_CR29","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/j.molimm.2011.05.001","volume":"48","author":"L Skattum","year":"2011","unstructured":"Skattum L, van Deuren M, van der Poll T, Truedsson L. Complement deficiency states and associated infections. Mol Immunol. 2011;48:1643\u201355. https:\/\/doi.org\/10.1016\/j.molimm.2011.05.001.","journal-title":"Mol Immunol"},{"key":"3630_CR30","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.molimm.2019.08.002","volume":"114","author":"J Schr\u00f6der-Braunstein","year":"2019","unstructured":"Schr\u00f6der-Braunstein J, Kirschfink M. Complement deficiencies and dysregulation: Pathophysiological consequences, modern analysis, and clinical management. Mol Immunol. 2019;114:299\u2013311. https:\/\/doi.org\/10.1016\/j.molimm.2019.08.002.","journal-title":"Mol Immunol"},{"key":"3630_CR31","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2147\/ijgm.S255298","volume":"13","author":"M Saito","year":"2020","unstructured":"Saito M, Harada S, Ogasawara R, Izumiyama K, Mori A, Morioka M, et al. Disseminated gonococcal infection associated with eculizumab therapy for paroxysmal nocturnal hemoglobinuria: a case report and literature review. Int J Gen Med. 2020;13:403\u20136. https:\/\/doi.org\/10.2147\/ijgm.S255298.","journal-title":"Int J Gen Med"},{"issue":"4","key":"3630_CR32","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1093\/cid\/ciy958","volume":"69","author":"PE Crew","year":"2019","unstructured":"Crew PE, Abara WE, McCulley L, Waldron PE, Kirkcaldy RD, Weston EJ, et al. Disseminated gonococcal infections in patients receiving eculizumab: a case series. Clin Infect Dis. 2019;69(4):596\u2013600. https:\/\/doi.org\/10.1093\/cid\/ciy958.","journal-title":"Clin Infect Dis"},{"key":"3630_CR33","unstructured":"Japanese Society of Hematology. Notes and countermeasures when using Soliris. Available from http:\/\/www.jshem.or.jp\/uploads\/files\/medical\/20180424%20Soliris.pdf. Accessed 19 July 2023. [In Japanese]."},{"key":"3630_CR34","unstructured":"Japanese Society of Nephrology. Notes and countermeasures when using Soliris. Available from https:\/\/www.jsn.or.jp\/topics\/notice\/_3430.php. Accessed 19 July 2023. [In Japanese]."},{"key":"3630_CR35","unstructured":"Japanese Society of Neurology. Notes and countermeasures when using Soliris. Available from https:\/\/www.neurology-jp.org\/news\/pdf\/news_20180109_01_04.pdf. Accessed 19 July 2023. [In Japanese]."},{"key":"3630_CR36","unstructured":"Japan Pediatric Society. Notes and countermeasures when using Soliris. Available from http:\/\/www.jpeds.or.jp\/uploads\/files\/201805Soliris.pdf. Accessed 19 July 2023. [In Japanese]."},{"issue":"1","key":"3630_CR37","doi-asserted-by":"publisher","first-page":"35","DOI":"10.4103\/ijn.IJN_336_18","volume":"30","author":"T Kise","year":"2020","unstructured":"Kise T, Fukuyama S, Uehara M. Successful treatment of anti-factor H antibody-associated atypical hemolytic uremic syndrome. Indian J Nephrol. 2020;30(1):35\u20138. https:\/\/doi.org\/10.4103\/ijn.IJN_336_18.","journal-title":"Indian J Nephrol"}],"updated-by":[{"DOI":"10.1007\/s12185-025-03921-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000}}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-023-03630-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-023-03630-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-023-03630-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T07:45:40Z","timestamp":1740555940000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-023-03630-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,29]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["3630"],"URL":"https:\/\/doi.org\/10.1007\/s12185-023-03630-x","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,29]]},"assertion":[{"value":"14 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12185-025-03921-5","URL":"https:\/\/doi.org\/10.1007\/s12185-025-03921-5","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"J.N. has received consulting fees from Alexion Pharma, Roche Pharmaceuticals, Chugai Pharmaceuticals, Novartis Pharmaceuticals, Apellis, Biocryst, and Sanofi; and holds patents (or patents are pending) with Roche Pharmaceuticals and Chugai Pharmaceuticals. T.K. has received payment or honoraria from Alexion Pharma. S.I. received support for this manuscript from Alexion Pharma; consulting fees and honoraria for lectures, presentations, and speakers\u2019 bureaus from Alexion Pharma; and served on an advisory board for a post-marketing surveillance for Alexion Pharma. H.M. received support in relation to providing study materials, medical writing, and article processing charges from Alexion Pharma and AstraZeneca Rare Diseases; consulting fees from Alexion Pharma, AstraZeneca Rare Diseases, argenx BVBA, and UCB; lecture fees from Japan Blood Products Organization and Chugai Pharmaceuticals; and served on advisory boards for post-marketing surveillance for Alexion Pharma and AstraZeneca Rare Diseases. T.N. has received lecture fees from Sanofi. S.M. received support in relation to providing study materials, medical writing, and article processing charges from Alexion Pharma; lecture fees from Alexion Pharma; and served on an advisory board for Alexion Pharma. A.S., T.M., Y.F., H.A., and H.H. are employees of and hold stock in Alexion Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}